These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
597 related articles for article (PubMed ID: 28288821)
1. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways. Chen F; Qin X; Xu G; Gou S; Jin X Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821 [TBL] [Abstract][Full Text] [Related]
2. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response. Chen F; Huang X; Wu M; Gou S; Hu W Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693 [TBL] [Abstract][Full Text] [Related]
3. Hybrid of DNA-targeting Chlorambucil with Pt(IV) Species to Reverse Drug Resistance. Chen F; Xu G; Qin X; Jin X; Gou S J Pharmacol Exp Ther; 2017 Nov; 363(2):221-239. PubMed ID: 28916659 [TBL] [Abstract][Full Text] [Related]
4. Novel platinum(IV) complexes conjugated with a wogonin derivative as multi-targeted anticancer agents. Qin X; Xu G; Chen F; Fang L; Gou S Bioorg Med Chem; 2017 Apr; 25(8):2507-2517. PubMed ID: 28314511 [TBL] [Abstract][Full Text] [Related]
5. Disruption of SSBs repair to combat platinum resistance via the JWA-targeted Pt(IV) prodrug conjugated with a wogonin derivative. Wang X; Li L; Pei S; Zhu Q; Chen F Pharmazie; 2020 Mar; 75(2):94-101. PubMed ID: 32213241 [TBL] [Abstract][Full Text] [Related]
6. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance. Li L; Huang X; Huang R; Gou S; Wang Z; Wang H Eur J Med Chem; 2018 Aug; 156():666-679. PubMed ID: 30031977 [TBL] [Abstract][Full Text] [Related]
7. Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance. Wang M; Li G; Jiang G; Cai J; Liu Z; Huang R; Huang X; Wang H J Med Chem; 2024 Apr; 67(8):6218-6237. PubMed ID: 38573870 [TBL] [Abstract][Full Text] [Related]
8. Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway. Xu X; Zhang Y; Li W; Miao H; Zhang H; Zhou Y; Li Z; You Q; Zhao L; Guo Q Biochem Pharmacol; 2014 Nov; 92(2):220-34. PubMed ID: 25264278 [TBL] [Abstract][Full Text] [Related]
9. Emerging JWA-targeted Pt(IV) prodrugs conjugated with CX-4945 to overcome chemo-immune-resistance. Chen F; Pei S; Wang X; Zhu Q; Gou S Biochem Biophys Res Commun; 2020 Jan; 521(3):753-761. PubMed ID: 31703842 [TBL] [Abstract][Full Text] [Related]
10. Wogonin inhibits H2O2-induced angiogenesis via suppressing PI3K/Akt/NF-κB signaling pathway. Zhou M; Song X; Huang Y; Wei L; Li Z; You Q; Guo Q; Lu N Vascul Pharmacol; 2014 Mar; 60(3):110-9. PubMed ID: 24534483 [TBL] [Abstract][Full Text] [Related]
11. DN604: A platinum(II) drug candidate with classic SAR can induce apoptosis via suppressing CK2-mediated p-cdc25C subcellular localization in cancer cells. Chen F; Jin X; Zhao J; Gou S Exp Cell Res; 2018 Mar; 364(1):68-83. PubMed ID: 29397071 [TBL] [Abstract][Full Text] [Related]
12. Salvia miltiorrhiza polysaccharide activates T Lymphocytes of cancer patients through activation of TLRs mediated -MAPK and -NF-κB signaling pathways. Chen Y; Li H; Li M; Niu S; Wang J; Shao H; Li T; Wang H J Ethnopharmacol; 2017 Mar; 200():165-173. PubMed ID: 28232127 [TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity. Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355 [TBL] [Abstract][Full Text] [Related]
14. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo. Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239 [TBL] [Abstract][Full Text] [Related]
15. Concurrent blockade of NF-κB and Akt pathways potentiates cisplatin's antitumor activity in vivo. Sun H; Zheng X; Wang Q; Yan J; Li D; Zhou Y; Lin Y; Zhang L; Wang X Anticancer Drugs; 2012 Nov; 23(10):1039-46. PubMed ID: 22760211 [TBL] [Abstract][Full Text] [Related]
16. Alternation of adriamycin penetration kinetics in MCF-7 cells from 2D to 3D culture based on P-gp expression through the Chk2/p53/NF-κB pathway. Lu M; Zhou F; Hao K; Liu J; Chen Q; Ni P; Zhou H; Wang G; Zhang J Biochem Pharmacol; 2015 Jan; 93(2):210-20. PubMed ID: 25478729 [TBL] [Abstract][Full Text] [Related]
17. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance. Huang X; Wang M; Wang C; Hu W; You Q; Yang Y; Yu C; Liao Z; Gou S; Wang H Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328 [TBL] [Abstract][Full Text] [Related]
18. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions. Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897 [TBL] [Abstract][Full Text] [Related]
19. Beclin1 affected by DN604 upregulates chemo-sensitivity of cervix SiHa cancer cells via inhibiting CK2-MRN-DSBs repair. Chen F; Sun S; Liu N; Pei S; Zhu Q; Wang X; Gou S Anticancer Drugs; 2019 Sep; 30(8):774-783. PubMed ID: 31274516 [TBL] [Abstract][Full Text] [Related]
20. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer. Kim EH; Jang H; Shin D; Baek SH; Roh JL Apoptosis; 2016 Nov; 21(11):1265-1278. PubMed ID: 27544755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]